Abstract
Chinese individuals in the U.S. have suffered substantial discrimination during the COVID19 pandemic, a stressor exacerbated by multiple minority identities (e.g., sexual and gender minority). This study aimed to explore the mechanisms of discriminatory experiences, specifically how it interacted with stressors like internalized homophobia and protective factors such as resilience, to affect depressive symptoms among Chinese individuals with multiple minority identities. Between 2022-2023, 272 Chinese LGB individuals residing in the U.S. (Mean[age]=28.36; SD=5.01) was surveyed anonymously using the Everyday discrimination Scale, the Internalized Homophobia Scale, the Conner-Davidson Resilience scale, and the Center for Epidemiologic Studies Depression Scale. Moderation and mediation analyses were conducted using STATA 17 and JASP 0.18.3. Replicating the positive association between discriminatory experience and depressive symptoms, we found that discrimination explained depressive symptoms directly and through increasing internalized homophobia. As a protective factor, resilience moderated the internalized homophobia-depressive symptoms link, but not the discrimination-depressive symptoms link. For Chinese LGB individuals with higher levels of resilience, the positive impact of internalized homophobia on depressive symptoms was weaker compared to those with lower resilience. Our findings further the understanding of the mediating and moderating mechanisms between discriminatory experiences and depressive symptoms among individuals with multiple minority identities. Continued research and intervention development on promoting resilience and other protective factors tailored to Chinese LGB individuals in the U.S. are crucial for improving mental health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was exempt from IRB review at Carilion Clinic (IRB-22-1558).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data underlying the results presented in the study are available from the corresponding author by reasonable request.
